Skip to main content
. 2019 Aug 6;15(8):e1007988. doi: 10.1371/journal.ppat.1007988

Fig 6. Pharmacological interrogation of ubiquitin-proteasome pathways in RNF121 KO cells.

Fig 6

A, AAV2-Luciferase expression of Scr and RNF121 KO Huh7 cells treated with PYR-41 (50uM). B, AAV2-Luciferase expression following transfection of dominant negative ubiquitin construct. C, AAV2-Luciferase expression of Scr and RNF121 KO Huh7 cells treated with MG132 (10uM). D, AAV2-Luciferase expression following treatment of Scr and RNF121 KO cells with DBeQ (10uM). Luciferase transgene expression was assessed at 24hrs post-transduction. A two-tailed unpaired t test was used unless otherwise indicated, with *, p<0.05; **, p<0.01; ***, p<0.005.